Korea Investment CORP Sells 56,956 Shares of Cencora, Inc. $COR

Korea Investment CORP lessened its holdings in Cencora, Inc. (NYSE:CORFree Report) by 32.8% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 116,478 shares of the company’s stock after selling 56,956 shares during the quarter. Korea Investment CORP owned approximately 0.06% of Cencora worth $36,403,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. United Bank lifted its position in shares of Cencora by 4.5% during the second quarter. United Bank now owns 7,032 shares of the company’s stock worth $2,109,000 after purchasing an additional 305 shares during the last quarter. Savant Capital LLC increased its stake in Cencora by 8.4% in the 2nd quarter. Savant Capital LLC now owns 8,251 shares of the company’s stock worth $2,474,000 after buying an additional 639 shares during the period. Fox Run Management L.L.C. purchased a new position in Cencora in the 2nd quarter worth about $448,000. AE Wealth Management LLC lifted its holdings in Cencora by 6.6% during the 2nd quarter. AE Wealth Management LLC now owns 20,792 shares of the company’s stock valued at $6,234,000 after buying an additional 1,283 shares in the last quarter. Finally, Los Angeles Capital Management LLC lifted its holdings in Cencora by 1,475.4% during the 2nd quarter. Los Angeles Capital Management LLC now owns 13,942 shares of the company’s stock valued at $4,181,000 after buying an additional 13,057 shares in the last quarter. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Insiders Place Their Bets

In other news, EVP Elizabeth S. Campbell sold 3,351 shares of the business’s stock in a transaction on Friday, December 19th. The stock was sold at an average price of $342.10, for a total value of $1,146,377.10. Following the completion of the transaction, the executive vice president directly owned 23,891 shares of the company’s stock, valued at approximately $8,173,111.10. The trade was a 12.30% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Silvana Battaglia sold 1,677 shares of the company’s stock in a transaction on Friday, December 19th. The stock was sold at an average price of $345.00, for a total value of $578,565.00. Following the sale, the executive vice president owned 18,796 shares of the company’s stock, valued at $6,484,620. This trade represents a 8.19% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 15,220 shares of company stock worth $5,282,867 over the last 90 days. Company insiders own 0.38% of the company’s stock.

Cencora Trading Up 0.9%

NYSE COR opened at $361.80 on Tuesday. The company has a debt-to-equity ratio of 3.62, a quick ratio of 0.51 and a current ratio of 0.92. The company has a market capitalization of $70.38 billion, a price-to-earnings ratio of 43.49, a price-to-earnings-growth ratio of 1.67 and a beta of 0.68. The company’s 50-day simple moving average is $354.60 and its two-hundred day simple moving average is $337.09. Cencora, Inc. has a one year low of $251.94 and a one year high of $377.54.

Cencora (NYSE:CORGet Free Report) last announced its quarterly earnings results on Wednesday, February 4th. The company reported $4.08 earnings per share for the quarter, topping the consensus estimate of $4.04 by $0.04. Cencora had a net margin of 0.50% and a return on equity of 176.54%. The firm had revenue of $85.93 billion during the quarter, compared to analysts’ expectations of $86.12 billion. During the same quarter in the prior year, the company earned $3.73 EPS. The company’s revenue was up 5.5% compared to the same quarter last year. Equities analysts forecast that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, March 2nd. Investors of record on Friday, February 13th were paid a $0.60 dividend. The ex-dividend date of this dividend was Friday, February 13th. This represents a $2.40 dividend on an annualized basis and a yield of 0.7%. Cencora’s payout ratio is 28.85%.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on COR. Barclays upped their target price on shares of Cencora from $400.00 to $425.00 and gave the stock an “overweight” rating in a research note on Friday, February 13th. JPMorgan Chase & Co. lifted their price target on shares of Cencora from $417.00 to $419.00 and gave the company an “overweight” rating in a research note on Tuesday, February 10th. Jefferies Financial Group upgraded Cencora from an “underperform” rating to a “buy” rating in a report on Thursday, January 22nd. Evercore dropped their price objective on Cencora from $440.00 to $420.00 and set an “outperform” rating on the stock in a research note on Thursday, February 5th. Finally, Wells Fargo & Company raised their price objective on Cencora from $405.00 to $429.00 and gave the stock an “overweight” rating in a report on Tuesday, February 10th. Eleven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $399.00.

Get Our Latest Stock Report on Cencora

About Cencora

(Free Report)

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.

See Also

Want to see what other hedge funds are holding COR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cencora, Inc. (NYSE:CORFree Report).

Institutional Ownership by Quarter for Cencora (NYSE:COR)

Receive News & Ratings for Cencora Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cencora and related companies with MarketBeat.com's FREE daily email newsletter.